Societe Generale Effekten (S28736) 시세

Look Jack! He’s swirling! Kerflumpkbok !

$BURU 8K February 07, 2025
https://ir.nuburu.net/financials/sec-filings/sec-filings-details/default.aspx?FilingId=18165603

Mike Tyson lost to Holyfield twice . . . lol. We need a better analogy. lol.

https://x.com/CyberluxC/status/1895089475258138990

$CBDW CEO Austen Lambrecht of 1606 Corp. stated, "Our AI solutions will further enhance GPOX's current AI usage to enhance its ability to manage complex logistics, optimize inventory, and deliver valuable insights that will transform the way convenience stores and gas stations operate. This collabor

$CBDW CEO Austen Lambrecht of 1606 Corp. stated, "Our AI solutions will further enhance GPOX's current AI usage to enhance its ability to manage complex logistics, optimize inventory, and deliver valuable insights that will transform the way convenience stores and gas stations operate. This collabor

BLMZ.............................................................p/m

$PHRRF PharmaTher expects to submit the MINOR AMENDMENT to the CRL by end-February 2025 and expects a new approval date for a Q2-2025 FDA approval of ketamine

TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM)

Why do you care why anyone is here? This is a strock discussion site.

Do your proper DD brothers and you will see TTX MC-138 is the only FDA Human clinical trial Mi-RNA in the world to destroy metastases and y’all now know it’s worth, A 4M market cap has never been seen in pharma history, this company has been shorted criminally, and management is completely useles

“This is the year that the hydrogen bubble pops, especially for transportation, but increasingly for all hydrogen for energy plays. One of the firms on my hydrogen death watch is Plug Power, which has managed to lose $3.12 billion of other people’s money since 2010, about $200 million a year on aver

Pulte is for the people..BOOOOOOM!!

Boom!

I do realise however if NLST wins there will be lic fees to bring in revenue...

$YGT.V $YGTFF Gold Terra Wedge Drilling Progressing Well at High-Grade Gold target,
https://www.accessnewswire.com/newsroom/en/metals-and-mining/gold-terra-wedge-drilling-progressing-well-at-high-grade-gold-target-campbell-shea-992428

$RENB David Weinstein, Chief Executive Officer of Renovaro (Nasdaq: RENB) commented, “We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatme

CRM
Stifel trims Salesforce price target, calls after-hours pullback 'overreaction'
Stifel lowered the firm's price target on Salesforce to $375 from $425 and keeps a Buy rating on the shares. Salesforce delivered quarter-over-quarter CRPO acceleration in Q4, a "bevy of AI disclosur

$YGT.V $YGTFF Gold Terra Wedge Drilling Progressing Well at High-Grade Gold target,
https://www.accessnewswire.com/newsroom/en/metals-and-mining/gold-terra-wedge-drilling-progressing-well-at-high-grade-gold-target-campbell-shea-992428

$RENB David Weinstein, Chief Executive Officer of Renovaro (Nasdaq: RENB) commented, “We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatme

“This is the year that the hydrogen bubble pops, especially for transportation, but increasingly for all hydrogen for energy plays. One of the firms on my hydrogen death watch is Plug Power, which has managed to lose $3.12 billion of other people’s money since 2010, about $200 million a year on aver

I was on vacation in Spain when he was in Eindhoven this month but I will definitely talk to him in Brussels during the PIC conference in April.

Wow that seems huge alto I have no Idea how much weight USIJ carries....

David Weinstein, Chief Executive Officer of Renovaro (Nasdaq: RENB) commented, “We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, a